Avelumab
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Merkel Cell Carcinoma
Conditions
Metastatic Merkel Cell Carcinoma
Trial Timeline
— → —
NCT ID
NCT03089658About Avelumab
Avelumab is a pre-clinical stage product being developed by Merck for Metastatic Merkel Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03089658. Target conditions include Metastatic Merkel Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Merkel Cell Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03089658 | Pre-clinical | Completed |
| NCT06412848 | Pre-clinical | Active |
| NCT05600127 | Phase 2 | Recruiting |
| NCT05431777 | Pre-clinical | Completed |
| NCT05366725 | Pre-clinical | Completed |
| NCT04822350 | Pre-clinical | Completed |
| NCT03815643 | Phase 3 | Active |
| NCT03514719 | Phase 1 | Completed |
| NCT03568097 | Phase 2 | UNKNOWN |
| NCT03827044 | Phase 3 | Terminated |
| NCT03674424 | Phase 2 | Completed |
| NCT03439501 | Phase 2 | UNKNOWN |
| NCT03147404 | Phase 2 | Completed |
| NCT03352934 | Phase 2 | Completed |
| NCT03389126 | Phase 2 | Completed |
| NCT03278379 | Phase 2 | Completed |
| NCT03278405 | Phase 1/2 | Completed |
| NCT03403777 | Phase 2 | Completed |
| NCT03491345 | Phase 2 | UNKNOWN |
| NCT03244176 | Phase 1 | Active |
Competing Products
20 competing products in Metastatic Merkel Cell Carcinoma